Abbott aims to recapture baby formula market share
Reuters
Published Jul 20, 2022 07:34AM ET
Updated Jul 20, 2022 12:01PM ET
By Leroy Leo and Amruta Khandekar
(Reuters) -Abbott Laboratories said on Wednesday it was set to recapture some of the market share in the baby formula business as the company restarts manufacturing at its troubled Michigan facility in the United States.
Abbott resumed partial production of certain specialty and metabolic formulas earlier this month at the Sturgis facility and has also imported products from its international plants.
The plant shutdown earlier this year and the recall of Abbott infant formula products deepened a supply shortage and sent parents in the United States scrambling.
"We've recovered already a good portion of the share that we lost," Abbott Chief Executive Robert Ford said on a conference call on Wednesday. "We continue to see that moving forward positively."
Before the recall, Abbott controlled 40% of the infant formula market, including Similac, but the market share of other companies such as Reckitt Benckiser Group PLC has grown since then.
Abbott said it plans to soon restart production of Similac, its milk-based infant formula. It has said it expects to begin releasing EleCare formula in the coming weeks.
Atlantic Equities analyst James Mainwaring expects the market share recovery for Abbott to be gradual.
The shortage, however, is yet to be alleviated, with in-stock nationwide availability of powder baby formula dipping to 69.6% for the week of July 3, from 70.7% in the week ended June 26, according to data service IRI.
Abbott's shares were down 2% after the company raised its annual forecast that some analysts called conservative.
The forecast "creates more questions than answers" as the small raise implies Abbott is cautious on its outlook for the second half, said Mainwaring.
Abbott said it now expects at least $4.90 per share in adjusted earnings in 2022, higher than its previous forecast of at least $4.70.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.